Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products.

Stromal-epithelial interactions and the bioactive molecules produced by these interactions maintain tissue homeostasis and influence carcinogenesis. Bioactive prostaglandins produced by prostaglandin synthases and secreted by the prostate into seminal plasma are thought to support reproduction, but their endogenous effects on cancer formation remain unresolved. No studies to date have examined prostaglandin enzyme production or prostaglandin metabolism in normal prostate stromal cells. Our results show that lipocalin-type prostaglandin D synthase (L-PGDS) and prostaglandin D2 (PGD2) metabolites produced by normal prostate stromal cells inhibited tumor cell growth through a peroxisome proliferator-activated receptor gamma (PPARgamma)-dependent mechanism. Enzymatic products of stromal cell L-PGDS included high levels of PGD2 and 15-deoxy-delta(12,14)-PGD2 but low levels of 15-deoxy-delta(12,14)-prostaglandin J2. These PGD2 metabolites activated the PPARgamma ligand-binding domain and the peroxisome proliferator response element reporter systems. Thus, growth suppression of PPARgamma-expressing tumor cells by PGD2 metabolites in the prostate microenvironment is likely to be an endogenous mechanism involved in tumor suppression that potentially contributes to the indolence and long latency period of this disease.

[1]  S. Fischer,et al.  Quantitative high-performance liquid chromatography/electrospray ionization tandem mass spectrometric analysis of 2- and 3-series prostaglandins in cultured tumor cells. , 2002, Analytical biochemistry.

[2]  Y. Urade,et al.  Lipocalin-type prostaglandin D synthase in human male reproductive organs and seminal plasma. , 1998, Biology of reproduction.

[3]  Fen Wang,et al.  Transgenic mouse with high cre recombinase activity in all prostate lobes, seminal vesicle, and ductus deferens , 2003, The Prostate.

[4]  J. Dacheux,et al.  Mammalian Lipocalin-Type Prostaglandin D2 Synthase in the Fluids of the Male Genital Tract: Putative Biochemical and Physiological Functions1 , 2002, Biology of reproduction.

[5]  P. D'Orléans-Juste,et al.  Role of ETB and B2 receptors in the ex vivo platelet inhibitory properties of endothelin and bradykinin in the mouse , 2001, British journal of pharmacology.

[6]  C. Glass,et al.  Peroxisome proliferator-activated receptors and retinoic acid receptors differentially control the interactions of retinoid X receptor heterodimers with ligands, coactivators, and corepressors , 1997, Molecular and cellular biology.

[7]  S. Narumiya,et al.  Function of prostanoid receptors: studies on knockout mice. , 2002, Prostaglandins & other lipid mediators.

[8]  Peter A. Jones,et al.  Establishment of conditional vectors for hairpin siRNA knockdowns. , 2003, Nucleic acids research.

[9]  Y. Boie,et al.  Molecular Cloning and Characterization of the Human Prostanoid DP Receptor (*) , 1995, The Journal of Biological Chemistry.

[10]  Peter Olson,et al.  Printed in U.S.A. Copyright © 2003 by The Endocrine Society doi: 10.1210/en.2003-0288 Minireview: Lipid Metabolism, Metabolic Diseases, and , 2022 .

[11]  P. Olson,et al.  Genetic deficiency in Pparg does not alter development of experimental prostate cancer , 2003, Nature Medicine.

[12]  I. Issemann,et al.  The mouse peroxisome proliferator activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene. , 1992, The EMBO journal.

[13]  J. Srigley,et al.  Seminal plasma biochemical markers and their association with semen analysis findings. , 1999, Urology.

[14]  H P Koeffler,et al.  Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. , 1998, Cancer research.

[15]  C. Glass,et al.  Differential recruitment of the coactivator proteins CREB-binding protein and steroid receptor coactivator-1 to peroxisome proliferator-activated receptor gamma/9-cis-retinoic acid receptor heterodimers by ligands present in oxidized low-density lipoprotein. , 2003, The Journal of endocrinology.

[16]  R. Matusik,et al.  Prostate cancer in a transgenic mouse. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[17]  J. Auwerx,et al.  PPARγ controls cell proliferation and apoptosis in an RB-dependent manner , 2003, Oncogene.

[18]  P. Stricker,et al.  Growth factor involvement in progression of prostate cancer. , 1998, Clinical chemistry.

[19]  A. Sabichi,et al.  Inverse relationship between 15-lipoxygenase-2 and PPAR-gamma gene expression in normal epithelia compared with tumor epithelia. , 2005, Neoplasia.

[20]  T. Mann.  Secretory function of the prostate, seminal vesicle and other male accessory organs of reproduction. , 1974, Journal of reproduction and fertility.

[21]  M. Gleave,et al.  Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. , 1991, Cancer research.

[22]  K. Sugamura,et al.  Selective expression of a novel surface molecule by human Th2 cells in vivo. , 1999, Journal of immunology.

[23]  A. Sabichi,et al.  Differential peroxisome proliferator-activated receptor-gamma isoform expression and agonist effects in normal and malignant prostate cells. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[24]  S. Hayward,et al.  Approaches to understanding the importance and clinical implications of peroxisome proliferator‐activated receptor gamma (PPARγ) signaling in prostate cancer , 2004, Journal of cellular biochemistry.

[25]  A. Brash,et al.  Discovery of a second 15S-lipoxygenase in humans. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[26]  P. Murdock,et al.  Prostaglandin D2 synthase enzymes and PPARgamma are co-expressed in mouse 3T3-L1 adipocytes and human tissues. , 2003, Prostaglandins & other lipid mediators.

[27]  G. Aumüller,et al.  Morphology and functions of the human seminal vesicle , 2009, Andrologia.

[28]  A. Sabichi,et al.  Differential expression of cyclooxygenase-2 and its regulation by tumor necrosis factor-alpha in normal and malignant prostate cells. , 2001, Cancer research.

[29]  J. Olsson.  Correlation between the concentration of beta-trace protein and the number of spermatozoa in human semen. , 1975, Journal of reproduction and fertility.

[30]  D. Tindall,et al.  Nonapoptotic cell death associated with S-phase arrest of prostate cancer cells via the peroxisome proliferator-activated receptor γ ligand, 15-deoxy-Δ12,14-prostaglandin J2 , 2000 .

[31]  R. Eliasson.  Biochemical analyses of human semen in the study of the physiology and pathophysiology of the male accessory genital glands. , 1968, Fertility and sterility.

[32]  K. Chien,et al.  PPARγ Is Required for Placental, Cardiac, and Adipose Tissue Development , 1999 .

[33]  R. Haché,et al.  Characterization of the prostaglandin receptors in human osteoblasts in culture. , 2001, Prostaglandins, leukotrienes, and essential fatty acids.

[34]  Jasmine Chen,et al.  The Peroxisome Proliferator‐activated Receptors: Ligands and Activators a , 1996, Annals of the New York Academy of Sciences.

[35]  R. Newman,et al.  Simultaneous quantification of arachidonic acid metabolites in cultured tumor cells using high-performance liquid chromatography/electrospray ionization tandem mass spectrometry. , 2001, Analytical biochemistry.

[36]  J. Challis.  Prostaglandins and reproduction—what do knockouts really tell us? , 1997, Nature Medicine.

[37]  H. Koeffler.  Peroxisome proliferator-activated receptor γ and cancers , 2003 .

[38]  L. Chung,et al.  Prostate tumor-stroma interaction: molecular mechanisms and opportunities for therapeutic targeting. , 2002, Differentiation; research in biological diversity.

[39]  C. Glass,et al.  Novel prostaglandin D(2)-derived activators of peroxisome proliferator-activated receptor-gamma are formed in macrophage cell cultures. , 2003, Biochimica et biophysica acta.

[40]  L. Chung,et al.  Molecular basis of co‐targeting prostate tumor and stroma , 2002, Journal of cellular biochemistry. Supplement.

[41]  H. Koeffler,et al.  RWJ-241947 (MCC-555), A Unique Peroxisome Proliferator-Activated Receptor-γ Ligand with Antitumor Activity against Human Prostate Cancer in Vitro and in Beige/Nude/ X-Linked Immunodeficient Mice and Enhancement of Apoptosis in Myeloma Cells Induced by Arsenic Trioxide , 2004, Clinical Cancer Research.

[42]  M. Magnuson,et al.  Generation and functional confirmation of a conditional null PPARγ allele in mice , 2002, Genesis.

[43]  G. Ayala,et al.  Reactive stroma in prostate cancer progression. , 2001, The Journal of urology.

[44]  Y. Thomassen,et al.  Accessory sex gland function in normal young (20-25 years) and middle-aged (50-55 years) men. , 1986, Journal of andrology.

[45]  Y. Kwak,et al.  RNA interference with small hairpin RNAs transcribed from a human U6 promoter-driven DNA vector. , 2003, Journal of pharmacological sciences.

[46]  R. Breyer.  Prostaglandin EP(1) receptor subtype selectivity takes shape. , 2001, Molecular pharmacology.

[47]  P. Scardino,et al.  Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[48]  M. Gerdes,et al.  Regulation of rat prostate stromal cell myodifferentiation by androgen and TGF‐β1 , 2004, The Prostate.

[49]  T. Kaneko,et al.  Dominant expression of mRNA for prostaglandin D synthase in leptomeninges, choroid plexus, and oligodendrocytes of the adult rat brain. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[50]  S. Cole,et al.  Use of the MTT assay for rapid determination of chemosensitivity of human leukemic blast cells. , 1988, Leukemia research.

[51]  Christopher K. Glass,et al.  The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation , 1998, Nature.

[52]  K. Sugamura,et al.  Gene structure and functional properties of mouse CRTH2, a prostaglandin D2 receptor. , 2003, Biochemical and biophysical research communications.